UK Secures Over 5 Million H5 Influenza Vaccine Doses as Pandemic Precaution

(Reuters) – Britain’s Health Security Agency (UKHSA) said on Tuesday that it has secured a contract for over five million doses of the human H5 influenza vaccine as part of preparations for a potential influenza pandemic.
The vaccine, which will be produced by the UK healthcare company CSL Seqirus UK Ltd, is intended for use only if the virus begins to spread among humans.
Currently, there is no evidence of such human-to-human transmission, according to the agency.

(Reporting by Yamini Kalia in Bengaluru; Editing by Tasim Zahid)
 
Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.